Article Information
History
- March 10, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Andrew M. Stern1,*,
- Kathryn L. Van Pelt2,*,
- Lei Liu1,
- Amirah K. Anderson1,
- Beth Ostaszewski1,
- Mark Mapstone3,
- Sid O’Bryant4,
- Melissa E. Petersen4,
- Bradley T. Christian5,
- Benjamin L. Handen6,
- Dennis J. Selkoe1,
- Frederick Schmitt2,
- Elizabeth Head7,**,
- the Alzheimer’s Biomarker Consortium – Down Syndrome (ABC-DS) investigators
- 1Ann Romney Center for Neurologic Diseases, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115
- 2Sanders-Brown Center for Aging, Department of Neurology, University of Kentucky, Lexington, KY 40508
- 3Department of Neurology, University of California, Irvine, Irvine, CA 92868
- 4University of North Texas Health Science Center, Fort Worth, TX 76107
- 5Waisman Center, University of Wisconsin-Madison, Madison, WI 53705
- 6Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA 15213
- 7Department of Pathology and Laboratory Medicine, University of California, Irvine, Irvine, CA 92697
- ↵**Correspondence to: Elizabeth Head, PhD, Department of Pathology and Laboratory Medicine, University of California, Irvine, 1111 Gillespie Neuroscience Research Facility, Irvine, CA 92697, heade{at}uci.edu
↵* Equal contribution
Posted March 10, 2023.
Plasma NT1-tau and Aβ42 correlate with age and cognitive function in two large Down syndrome cohorts
